-+ 0.00%
-+ 0.00%
-+ 0.00%
Roche Secures De Novo Approval from US FDA for Mass Spectrometry Platform with Ionify Gabapentin Assay
Share
Listen to the news
09:41 AM EST, 11/16/2026 (MT Newswires) -- Roche (RO.SW) secured De Novo authorization from the US Food and Drug Administration for its cobas pro i 601 platform with the Ionify Gabapentin assay for mass spectrometry testing. The Swiss drugmaker said Monday it will use a Predetermined Change Control Plan approved by the FDA to expand its future clinical mass spectrometry menu on the platform to up to 22 Ionify assays. The cobas pro i 601 platform with the Ionify Gabapentin assay combines mass spectrometry with an automated, standardized workflow to provide advanced testing to routine clinical laboratories.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending